| 5.08 0.02 (0.4%) | 05-03 11:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.54 |
1-year : | 7.63 |
| Resists | First : | 5.59 |
Second : | 6.54 |
| Pivot price | 5.04 |
|||
| Supports | First : | 4.96 |
Second : | 4.57 |
| MAs | MA(5) : | 5.16  |
MA(20) : | 5.05 |
| MA(100) : | 5.02 |
MA(250) : | 4.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 57.1 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 6.96 | Low : | 2.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVNO ] has closed below upper band by 44.5%. Bollinger Bands are 28.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.23 - 5.27 | 5.27 - 5.3 |
| Low: | 4.95 - 4.99 | 4.99 - 5.02 |
| Close: | 5.01 - 5.07 | 5.07 - 5.11 |
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Tue, 30 Apr 2024
enVVeno Medical (NASDAQ:NVNO) Trading 0.8% Higher - MarketBeat
Tue, 30 Apr 2024
enVVeno Medical (NASDAQ:NVNO) Shares Up 0.8% - Defense World
Wed, 24 Apr 2024
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve ... - Miami Herald
Tue, 16 Apr 2024
enVVeno Medical to present VenoValve trial data at symposium - Investing.com
Tue, 16 Apr 2024
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual ... - Sacramento Bee
Tue, 09 Apr 2024
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer - AccessWire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 13 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 35 (%) |
| Shares Short | 822 (K) |
| Shares Short P.Month | 739 (K) |
| EPS | -1.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35 % |
| Return on Equity (ttm) | -55.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.68 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|